GPR40-Activating Hex-4-inoic Acid Derivative for Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, particularly type II diabetes, face challenges such as inducing low blood sugar, weight gain, gastrointestinal issues, and loss of drug effectiveness over time, highlighting the need for a more efficient and safe method to regulate blood glucose and promote insulin secretion.
Innovation Solution
A novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and its pharmaceutically acceptable salts or optical isomers, which activate the GPR40 receptor, thereby increasing intracellular calcium concentration and promoting insulin secretion without toxicity when co-administered with other drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current diabetes treatment methods are used, then blood glucose can be lowered, but side effects occur such as low blood sugar, weight gain, gastrointestinal issues, and loss of drug effectiveness
Solution Approach 1:
The patent develops a novel chemical compound with a specific molecular structure (3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative) that activates GPR40 receptors. This represents a fundamental change in the chemical parameter approach, creating a new substance with optimized properties that achieves blood glucose lowering without the harmful side effects of conventional treatments
Solution Approach 2:
The invention introduces GPR40 receptor as an intermediary mechanism between the administered compound and the physiological response. The compound acts as a mediator that selectively binds to and activates GPR40 receptors in pancreatic beta cells, thereby promoting insulin secretion in a glucose-dependent manner without causing the harmful side effects associated with direct insulin administration or other conventional approaches
2Quantity of substance
If insulin secretion is promoted, then blood glucose control improves, but risk of low blood sugar increases
Solution Approach 1:
The patent describes a dynamic mechanism where GPR40 activation leads to glucose-dependent insulin secretion. The system adapts its response based on the glucose level - when glucose is high, insulin secretion is promoted; when glucose is low, the effect is reduced. This dynamic response prevents hypoglycemia while maintaining effective glucose control
Solution Approach 2:
The invention utilizes a feedback mechanism where the activation of GPR40 receptors by the compound creates a regulated insulin secretion response that is modulated by cellular calcium concentration and glucose levels. This feedback system ensures that insulin secretion is appropriately regulated and does not lead to excessive lowering of blood glucose
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient for the prevention and treatment of metabolic disease. The novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention has excellent activities of activating GPR40 protein and promoting insulin secretion accordingly but has no toxicity when co-administered with other drugs. That is, the novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention can be co-administered with other drugs and can promote the activation of GPR40 protein significantly, so that the composition comprising the same as an active ingredient can be efficiently used as a pharmaceutical composition for the prevention and treatment of metabolic disease such as obesity, type I diabetes, type II diabetes, incompatible glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome X, etc.